**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:** CAN/2015-16/443

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | LAMIVUDINE 300 mg and TENOFOVIR DISOPROXIL FUMARATE 300 mg TABLETS | | REF. NO: NDQB201602757 |
| **DATE RECEIVED:** 18.02.2016 | **LABEL CLAIM:** | Each film coated tablet contains Tenofovir disoproxil fumarate 300 mg equivalent to Tenofovir disoproxil 245 mg and Lamivudine USP 300 mg. | |
| **BATCH NO.:** ELC4509A | **PRESENTATION:** | White coloured, caplet-shaped, biconvex faced tablets, embossed 'CL 71' on one face and plain on the other, packed in a white plastic multi-dose container carrying 30 tablets in a unit box. | |
| **MGF. DATE:** Dec. 2015 | **MANUFACTURER:** | MACLEODS Pharmaceuticals Ltd. | |
| **EXP. DATE:**  Nov. 2017 | **ADDRESS:** | Plot No. 25-27, Survey No. 366, Premier Ind. Estate,Kachigam, Daman - 396 210 (U.T.), Off.: Atlanta Arcade, Marol Church Road, Andheri (E), Mumbai 400 059, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | Kenya Medical Supplies Authority, P.O. Box 47715 - 00100, Nairobi, KENYA | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | BP 2016 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean tablet weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC | Adopted In-House Method | RT of the component peaks in the assay sample preparation correspond to those in the assay standard preparation | Super-imposable peaks at RT 4.2 and 16.4 -/+ 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80.0% (n=6):No tablet less than 85.0% (n=6) | Lamivudine 97.40% (RSD=0.70%, n=6) | **:** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80.0% (n=6):No tablet less than 85.0% (n=6) | Tenofovir DF 97.31% (RSD=0.47%, n=6) | **:** |
| **Assay** | HPLC | Adopted In-House Method | 90.0 - 110.0% | Lamivudine 97.04% (RSD=0.24%, n=9) | **:** |
| **Assay** | HPLC | Adopted In-House Method | 90.0 - 110.0% | Tenofovir DF 96.35% (RSD=0.58%, n=9) | **:** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| ANALYST: | DR. L. KARANJA |  | DATE:01-03-2016 |
| ANALYST: | DR. E. TANUI |  | DATE:03-03-2016 |
| ANALYST: | NICHOLAS MWAURA |  | DATE:03-07-2016 |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:03-09-2016 |